Rivus Pharmaceuticals
Phase 2Rivus Pharmaceuticals, a leader in mitochondrial biology, is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity.
Founded
2019
Focus
Small Molecules
About
Rivus Pharmaceuticals, a leader in mitochondrial biology, is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity.
Funding History
2Total raised: $167M
Series B$35MBain Capital Life SciencesMay 15, 2023
Series A$132MBain Capital Life SciencesJan 15, 2022
Company Info
TypePrivate
Founded2019
LocationDurham, United States
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile